CVC has developed a proprietary antigen designed to induce what is known as a cytotoxic immune response. This type of immune response primes the immune system to specifically kill only those cells that have become infected with virus. There are very few COVID-19 vaccines in development that take an approach that is focussed specifically on a cytotoxic immune response. 

We have the option of displaying our antigen on the surface of biobeads. CVC has access to a well-researched technology originally developed at Massey University in Palmerston North, New Zealand. The technology enables the efficient production of tiny biobeads that are coated in whatever protein or polypeptide one chooses. In our case, these biobeads could be coated in a proprietary polypeptide derived from parts of the SARS-Cov-2 virus.

Round biobeads that have formed inside a bacterium

The main aspects of the biobeads technology are: